FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to neurology, neurooncology, and can be applied when it is necessary to deliver medications through blood-brain barrier (BBB). For this purpose intracarotidly ozonised physiological solution is introduced intracarotidly. Introduction is performed once with ozone concentration 0.7 mg/l and ozone dose 0.0035 mg/kg.
EFFECT: method allows to ensure increase of BBB permeability with simultaneous reduction of number of complications due to use of ozone, which in process of decay forms metabolites participating in various reactions at the cell level.
1 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING MALIGNANT BRAIN TUMOURS | 2010 |
|
RU2418587C1 |
| NON-INVASIVE METHOD FOR IMPROVING PERMEABILITY OF HEMATOENCEPHALIC BARRIER | 2017 |
|
RU2688013C1 |
| METHOD FOR LOCALISING CEREBRAL OEDEMA ACCOMPANYING CEREBRAL TUMOUR | 2012 |
|
RU2479842C1 |
| METHOD FOR DELIVERING NANOPARTICLES INTENDED FOR THE TRANSPORT OF DRUGS TO THE BRAIN OF MAMMALS THROUGH THE BLOOD-BRAIN BARRIER | 2017 |
|
RU2670091C1 |
| METHOD OF TREATING CEREBRAL OEDEMA IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASES | 2014 |
|
RU2539139C1 |
| POLYPEPTIDE CAPABLE OF OVERCOMING HEMATOENCEPHALIC BARRIER, AND CONJUGATE THEREOF | 2005 |
|
RU2408605C2 |
| APROTININ POLYPEPTIDES FOR TRANSPORT OF COMPOUND THROUGH BLOOD-BRAIN BARRIER | 2010 |
|
RU2611193C2 |
| METHOD FOR ASSESSING THE FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P IN THE BLOOD-BRAIN BARRIER | 2018 |
|
RU2677286C1 |
| GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
| PHARMACEUTICAL COMBINATION INFLUENCING CENTRAL NERVOUS SYSTEM FUNCTION; METHOD OF CORRECTING CONDITIONS ASSOCIATED WITH DYSFUNCTION OF CENTRAL NERVOUS SYSTEM; PHARMACEUTICAL KIT; AGENT ASSISTING THERAPEUTICAL SUBSTANCES AND METABOLITES TO CROSS BLOOD-BRAIN BARRIER; AND ENDONASAL DRUG | 2004 |
|
RU2253461C1 |
